Kornimate/medical-research-clean huggingface dataset:
anesthetic techniques in ep patients

Conditions: Cardiac Disease

Summary: the purpose of this study is to compare different combinations of anesthetic drugs (cause loss of sensation) in terms of effectiveness, adverse effects, pain relief, and patient comfort for cardiac electrophysiology procedures. in addition, the investigators are studying the different anesthetic combinations to determine the best approach in terms of identification and treatment of arrhythmias.

anesthetic management in patients coming for electrophysiology procedures is extremely important and hemodynamically challenging in order to minimize interference on the electrophysiology studies (eps) and the ability to trigger arrhythmias while also maintaining patient comfort and limited movement. various anesthetic combinations are administered to provide sedation, analgesia/sedation, or general anesthesia. the ideal agent should produce rapid loss of consciousness while ensuring cardiovascular stability and prompt recovery with few adverse effects. our goal is to study anesthetic techniques and the effect on electrophysiology procedures to determine the best anesthetic combination in terms of effectiveness, adverse effects, pain relief, and patient comfort. adult patients scheduled for electrophysiology procedures will be enrolled in the study and randomly assigned to an anesthetic group based on their schedule procedure. sedation cases for supraventricular tachycardia (svt), right ventricular outflow tract (rvot)/premature ventricular contraction (pvc) ablation, and atrial flutter (aflutter) procedures will be randomly assigned to one of three groups: 1) monitored anesthesia (local anesthesia with sedation and analgesia/pain reliever) with propofol (induce sleep), 2) monitored anesthesia with ketamine (sedation) + propofol (induce sleep), or 3) monitored anesthesia with remifentanil infusion (pain reliever) + propofol (induce sleep). sedation cases for ventricular tachycardia (vt) ablation and atrial fibrillation (afib) procedures will be randomly assigned to one of two groups: 1) monitored anesthesia (local anesthesia with sedation and analgesia/pain reliever) with propofol (induce sleep), or 2) monitored anesthesia with ketamine (sedation) + propofol (induce sleep). general anesthesia (ga) cases, including vt ablation and afib procedures will receive general anesthesia (state of unconsciousness) with sevoflurane (loss of consciousness) + o2. anesthesia factors, such as hemodynamics and cerebral oxygen saturation will be continuously monitored and recorded throughout the study. in addition, we will be looking at standard echocardiogram and electrophysiology (ep) parameters. the patient's pain level, level of sedation, and satisfaction will also be measured using scales, assessments, and surveys.

Eligibility criteria:
inclusion criteria: * patients scheduled for cardiac electrophysiology procedures * patients ≥18 years of age exclusion criteria: * gastroesophageal reflux disease (gerd), * pulmonary hypertension, * severe pulmonary disease, * obstructive sleep apnea (osa) with continuous positive airway pressure therapy (cpap)

Keywords: electrophysiology anesthetics
an observational study in rheumatoid arthritis patients treated with roactemra/actemra (tocilizumab)

Conditions: Rheumatoid Arthritis

Summary: this multi-center, observational study will evaluate the clinical practice patterns, efficacy and safety of roactemra/actemra (tocilizumab) in patients with rheumatoid arthritis. data will be collected from each eligible patient initiated on roactemra/actemra treatment by their treating physician according to approved label for up to 12 months from start of treatment.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * moderate to severe rheumatoid arthritis * patients for whom the treating physician has made the decision to commence roactemra/actemra treatment. in group a roactemra/actemra has been prescribed within 8 weeks prior to the enrolment visit. in group b roactemra/actemra has been started more than 8 weeks before inclusion in the study, but not before january 2011 exclusion criteria: * roactemra/actemra treatment more than 8 weeks prior to inclusion visit for group a, before january 2011 for group b * previous roactemra/actemra treatment in a clinical trial or for compassionate use * treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with roactemra/actemra * history of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis
study comparing lutonix av drug coated balloon vs standard balloon for treatment of dysfunctional av fistulae

Conditions: Arteriovenous Fistula

Summary: this prospective, global, multicenter, randomized, controlled study is designed to evaluate the safety and effectiveness of the lutonix 035 av drug coated balloon pta catheter compared to a standard pta catheter in treating subjects presenting with clinical and hemodynamic abnormalities in native arteriovenous (av) fistulae located in the upper extremity.


Eligibility criteria:
inclusion criteria: 1. age ≥21 years; 2. the subject is legally competent, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions, and has duly signed the informed consent form (icf); 3. arteriovenous fistula located in the arm; 4. native av fistula was created ≥30 days prior to the index procedure and has undergone one or more hemodialysis sessions; 5. venous stenosis of an av fistula with the target lesion located from the anastomosis to the axillosubclavian junction and an abnormality attributable to the stenosis as defined by k/doqi guidelines.; 6. successful pre-dilation of the target lesion with a percutaneous transluminal angioplasty (pta) balloon; 7. intended target lesion. exclusion criteria: 1. women who are pregnant, lactating, or planning on becoming pregnant during the study; 2. hemodialysis access is located in the leg; 3. subject has more than two lesions in the access circuit; 4. subject has a secondary non-target lesion that cannot be successfully treated; 5. target lesion is located central to the axillosubclavian junction; 6. the subject has a secondary lesion located in the central venous system (central to the axillosubclavian junction); 7. a thrombosed access; 8. surgical revision of the access site planned; 9. recent prior surgical interventions of the access site; 10. other planned treatment during the index procedure; 11. known contraindication (including allergic reaction) or sensitivity to iodinated contrast media, that cannot be adequately managed with pre-and post-procedure medication; 12. known contraindication (including allergic reaction) or sensitivity to paclitaxel. 13. subjects who are taking immunosuppressive therapy or are routinely taking ≥10mg of prednisone per day; 14. subject has another medical condition, which, in the opinion of the investigator, may cause him/her to be noncompliant with the protocol or confound the data interpretation; 15. subject has a life expectancy \<12 months; 16. anticipated for a kidney transplant; 17. anticipated conversion to peritoneal dialysis; 18. subject has a stent located in the target or secondary non target lesion; 19. subject has an infected av access or systemic infection; 20. currently participating in an investigational drug, biologic, or device study, or previous enrollment in this study.
quetiapine for primary insomnia patients : a randomized controlled trial

Conditions: Primary Insomnia

Summary: primary insomnia patients will sleep with quetiapine not better than without quetiapine

1. primary insomnia will be diagnosed according to dsm-iv-tr 2. after consenting, cases will be divided (double blind randomization)in to two arms 2.1 sleep hygiene with placebo group 2.2 sleep hygiene with quetiapine group 3. outcome measurement: sleep diary, sleep satisfaction visual analog scale and sleep satisfaction likert scale 4. statistical method: dependent t test

Eligibility criteria:
inclusion criteria: * primary insomnia patients by dsm-iv-tr criteria * cases enrolled: age 18-65 educated exclusion criteria: * currently receiving quetiapine or other hypnotic drugs * liver disease * patients with heart dz, hypertension, thyroid disease * history of epilepsy or febrile convulsion * pregnant * cognitive impairments * history of orthostatic hypotension * patient with other psychiatric conditions or drug dependence

Keywords: primary insomnia quetiapine randomized controlled trial double blind
a performance evaluation of the harmony 1 sensors in adults and pediatrics

Conditions: Type 1 Diabetes; Type 2 Diabetes

Summary: the purpose of this study is to demonstrate the performance of the harmony 1 sensor in subjects age 2 - 75 years

this study is a multi-center, randomized, prospective single-sample correlational design without controls. a total of up to 310 previously-diagnosed type 1 or 2 diabetes subjects will be enrolled in order to have 160 subjects complete frequent sample testing at up to 17 centers. subjects will wear harmony 1 sensors used with the guardian mobile application.

Eligibility criteria:
inclusion criteria: * subject is 2-75 years of age at time of screening * a clinical diagnosis of type 1 or 2 diabetes for a minimum of 12 months duration as determined via medical record or source documentation by an individual qualified to make a medical diagnosis * adequate venous access as assessed by investigator or appropriate staff * subjects participating in the high and low glucose challenges must have an established insulin carbohydrate ratio(s) and insulin sensitivity ratio. (the term "established" refers to a ratio that has been previously defined and tested prior to screening visit). subjects without established ratios may participate under observation only. exclusion criteria: * subject will not tolerate tape adhesive in the area of harmony 1 sensor placement as assessed by qualified individuals * subject has any unresolved adverse skin condition in the area of harmony 1 sensor or device placement (e.g., psoriasis, rash, staphylococcus infection) * subject is actively participating in an investigational study (drug or device) wherein they have received treatment from an investigational study (drug or device) in the last 2 weeks * subject is female and has a positive pregnancy screening test * females of child bearing age and who are sexually active should be excluded if they are not using a form of contraception deemed reliable by investigator * subject is female and plans to become pregnant during the course of the study * subject has had a hypoglycemic seizure within the past 6 months * subject has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to screening visit * subject has had an episode of diabetic ketoacidosis (dka) within the past 6 months prior to screening visit. * subject has a history of a seizure disorder * subject has central nervous system or cardiac disorder resulting in syncope * subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (tia), cerebrovascular accident (cva), angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease * subject has a hematocrit (hct) lower than the normal reference range * subject has a history of adrenal insufficiency

Keywords: type 1 diabetes type 2 diabetes harmony 1
effects of lactobacillus crispatus lcr86 on bacterial vaginosis and ovarian function in women

Conditions: Patients With Bacterial Vaginosis

Summary: lactobacillus crispatus lcr86 was selected as a test preparation to observe its clinical efficacy in an intervention trial of combined antibiotic treatment and evaluate its effect on the cure rate, recurrence rate and vaginal flora of patients with bacterial vaginitis.


Eligibility criteria:
inclusion criteria: 1. 18 to 65 years of age, history of sexual activity, premenopausal women; 2. nugent score ≥ 7 for diagnosis of bv; 3. signed informed consent. exclusion criteria: 1. mixed vaginitis, such as vulvovaginal candidiasis (vvc), trichomonas vaginalis (tv) infection, chlamydia trachomatis (ct) infection, or gonococcal vaginitis; 2. history of systemic organic or psychiatric disease; 3. planned pregnancy, breastfeeding, or menstruation; 4. have used any antibiotics within 5 days of disease onset; 5. long-term use of contraceptives or immunosuppressants; 6. hypersensitivity or allergy to known components of the study drug.
decision-aid for renal therapy pilot trial

Conditions: Renal Insufficiency, Chronic; Kidney Failure, Chronic

Summary: successful communication between patients, caregivers, and physicians can improve how patients feel about their treatment. our recent studies of older dialysis patients find, however, that many patients do not engage in this type of communication about treatment options. this study aims to determine whether the decision-aid for renal therapy (dart), a web-based program, can improve shared decision-making (decisions where patients are actively engaged) among patients, caregivers, and physicians, and improve certainty and satisfaction in treatment decisions.

successful end-of-life communication between patients, caregivers, and physicians is associated with superior psychosocial outcomes, less intensive treatment, greater satisfaction, and higher likelihood of death at home. the decision-aid for renal therapy (dart) is an interactive web-based decision-aid that can empower patients and caregivers to select the treatment choice for chronic kidney disease that best suits them. dart was developed using a rigorous, validated, patient-engaged process and helps clarify decision-points and tradeoffs by providing individualized information about outcomes that matter most to patients. dart is designed to promote shared decision-making between patients, caregivers, and physicians and align preferences with treatment received. although proven effective and in current use in the general population, dart's effectiveness in an older population is unclear. the purpose of this project is to conduct a pilot study of dart's feasibility and effectiveness to improve end-of-life planning and shared decision-making among older end-stage renal disease patients.

Eligibility criteria:
inclusion criteria: * chronic kidney disease stages 4 or 5, not currently on dialysis * age \>=70 * english-speaking * willingness to be randomized to dart * able to sign informed consent * 5-year kidney failure risk probability \> 15% using \[www.kidneyfailurerisk.com\] * glomerular filtration rate (gfr) \< 30 exclusion criteria: * non-english speaking
beetroot juice ingestion and vertical jump performance

Conditions: Dietary Supplements

Summary: beetroot juice is a dietary supplement with good evidence for improving sports performance in different sport contexts, however, the evidence about the effects of beetroot juice in jump capacity is unclear. thus, the aim of this study was to conduct a comprehensive examination of beetroot juice effects on vertical jump performance

beetroot juice is a dietary supplement with good evidence for improving sports performance in different sport contexts, however, the evidence about the effects of beetroot juice in jump capacity is unclear. therefore a deeper knowledge about the effects of beetroot juice on several components of vertical jump performance remain largely unexplored between we can mention phase duration peak power, average power, peak velocity, initial force, and peak force. thus, the aim of this study was to conduct a comprehensive examination of beetroot juice effects on several countermovement jump components.

Eligibility criteria:
inclusion criteria: experience in resistance training (at least 18 months of three weekly sessions). a one-repetition maximum weight (1 rm) higher than bodyweight in the bench press and of 1.5 of body weight in squat exercise no sports supplement was taken in the previous three months no smoking. no cardiovascular, pulmonary or neurological disease. to not be considered an elite athlete. exclusion criteria: age \ 35 years.
impact of disease on the concept of end-of-life decisions of the elderly in the community

Conditions: Sick Elderly

Summary: the purpose of this study is to determine the priorities of the elderly in the community about end-of-life decisions. to check the perception of the disease in the elderly in the community.

this study is descriptive adapters which examines the relationship between illness perception and preferences of end of life decisions in the elderly in the community. population and sample: the target population will be elderly and healthy community elderly population was accessible due to a special branch of the club together in the center of the country. sample to be a sample of convenience. the study will include 88 seniors aged 65 and over to get the power of 0.80 and alfa 0.05, tools: the study used three tools. * the first tool is a questionnaire on demographic and clinical details * the second tool questionnaire the long term support program (ltsp) * the third tool is a questionnaire perception of the disease revised illness perceptions questionnaire (ipqr) the research process: investigator will present the proposal to the commissioner fund hospitals and request approval for the study. after receiving approval from the director department of health fund the hospital will make data collection phase hmo, days and hours of reception. interrogator he is to partition the questionnaires and will be present when filling out the questionnaires to help, if and created a situation of lack of understanding of the questionnaires. scholar, came to the population for the disabled arriving at the clinic visit, and introduce himself and the subject of research. investigator will indicate questionnaire is anonymous.

Eligibility criteria:
inclusion criteria: * chronic illness * literate in hebrew * treated in community hmo exclusion criteria: * someone hospitalized in previous year * history of mental illness * cognitive problems

Keywords: end of life decisions perception of illness
long-term safety and tolerability of hsk39297 in patients with paroxysmal nocturnal hemoglobinuria

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Summary: this is a multicenter, open-label study to evaluate the long-term safety, tolerability and efficacy of hsk39297. adult patients with pnh who had previously received and completed hsk39297 study treatment will be included. eligible subjects can maintain hsk39297 treatment until the end of the study.


Eligibility criteria:
inclusion criteria: 1. patients with pnh who have previously received and completed hsk39297 treatment , and according to the researchers' judgment, the benefits of treatment outweigh the risks and may benefit from continued treatment with hsk39297; 2. understand the study procedures and methods, voluntarily participate in this trial. exclusion criteria: 1. hereditary or acquired complement deficiency; 2. active primary or secondary immunodeficiency; 3. history of splenectomy, bone marrow/ hematopoietic stem cell or solid organ transplants; 4. history of recurrent invasive infections caused by encapsulated organisms( e.g. meningococcus or pneumococcus) or mycobacterium tuberculosis; 5. history of serious comorbidities that have been determined to be unsuitable for participation in the study; 6. pregnant or lactating women.
raltegravir + lamivudine/abacavir in hiv/tuberculosis co-infected patients

Conditions: HIV Infections; Tuberculosis

Summary: the study will investigate whether combination antiretroviral therapy of raltegravir and 3tc/abc is effective and safe to use in tuberculosis (tb)/hiv co-infected adults receiving rifabutin-containing, first-line antituberculous treatment. hypothesis:combination antiretroviral therapy of raltegravir and 3tc/abc and is effective and safe to use in tuberculosis (tb)/hiv co-infected adults receiving rifabutin-based first-line antituberculous treatment.

this is a phase iiib/iv, open-label, multi-center, single-arm descriptive pilot study of the efficacy and safety of ral bid in combination with abc/3tc qd in antiretroviral-naïve hiv-1 infected individuals with a presumptive or confirmed diagnosis of tuberculosis, without planned comparative analyses. a goal of 40 subjects will be enrolled from 3 sites in the russian federation, including in our site, and receive ral bid + 3tc/abc qd for 48 weeks. this study will include screening, treatment and follow-up periods. screening period up to 28 days includes initial visits at day -28 (screening) and day -14 (switch to rifabutin). the second visit will be required if patient is initially on rifampin-based tb regimen that will need to be switched to rifabutin-based regimen. patients receiving rifampin-containing tb therapy will be switched to rifabutin (300 mg daily) a minimum of 14 days prior to initiation of antiretroviral therapy. patients must not have received more than 45 days of tuberculosis therapy. treatment period from day 1 to week 48 includes 7 visits and a follow-up period (2-4 weeks after the week 48 visit or withdrawal visit) includes one visit for resolution of ongoing aes (adverse events) and new saes (serious adverse events). patients will therefore have 10 scheduled assessments: screening (day -28; day -14), baseline (day 1), weeks 4, 8, 12, 24, 36, and 48, and follow-up visit.

Eligibility criteria:
inclusion criteria: * art-naïve hiv infected patients * plasma hiv-1 rna \>1,000 copies/ml at screening * cd4 cells 100-350 cells/mm3 * have presumptive or confirmed diagnosis of mycobacterium tuberculosis infection * receiving first-line antituberculosis treatment * documented negative results for the presence of hla-b\*5701 allele exclusion criteria: * pregnancy and breastfeeding * known allergy/sensitivity to study drugs or their formulations * a condition (including but not limited to active alcohol or drug use) that, in the opinion of the investigator, may interfere with patient adherence or safety